Ann: Quarterly Cashflow and Market Update September 2021, page-20

Hi Scott

I think Layton may have a point here.

Trying to scale unregistered medicines via SAS is expensive, futile and will lead to the same negative operating margins like AGH, CAU, LGP, etc

Trying to make registered medicines which is what Layton is recommending is a much more sophisticated strategy and one which is likely have much higher barriers to entry than SAS.

I support Layton's plans to not gobble the low hanging fruit (unregistered SAS CBD/cannabis oil) and instead aim to register a novel medicine (animal or human)

it is the barriers to entry which allow the generation of a higher price and hence profitability.

IMHO GLTA DYOR